Literature DB >> 27573221

Pharma pumps up anti-tau Alzheimer pipeline despite first Phase III failure.

Asher Mullard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27573221     DOI： 10.1038/nrd.2016.176

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  5 in total

Review 1.  Clinical Research on Alzheimer's Disease: Progress and Perspectives.

Authors:  Bin-Lu Sun; Wei-Wei Li; Chi Zhu; Wang-Sheng Jin; Fan Zeng; Yu-Hui Liu; Xian-Le Bu; Jie Zhu; Xiu-Qing Yao; Yan-Jiang Wang
Journal:  Neurosci Bull       Date:  2018-06-28       Impact factor: 5.203

Review 2.  Tau-based therapies in neurodegeneration: opportunities and challenges.

Authors:  Chuanzhou Li; Jürgen Götz
Journal:  Nat Rev Drug Discov       Date:  2017-10-06       Impact factor: 84.694

Review 3.  2D versus 3D human induced pluripotent stem cell-derived cultures for neurodegenerative disease modelling.

Authors:  Eduarda G Z Centeno; Helena Cimarosti; Angela Bithell
Journal:  Mol Neurodegener       Date:  2018-05-22       Impact factor: 14.195

4.  New Drug Research and Development for Alzheimer's Pathology: Present and Prospect.

Authors:  Tao Wang
Journal:  Shanghai Arch Psychiatry       Date:  2017-08-25

5.  Re-thinking Alzheimer's disease therapeutic targets using gene-based tests.

Authors:  Man Ki Kwok; Shi Lin Lin; C Mary Schooling
Journal:  EBioMedicine       Date:  2018-10-09       Impact factor: 8.143
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.